Ascendis Pharma A/S (NASDAQ:ASND) clinical stage biopharmaceutical firm, is expected to report third quarter earnings results, after market close, on Wednesday 11th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 1.88 per share.
Looking ahead, the full year loss are expected at $ 7.61 per share on the revenues of $ 8.67 million.
Previous Quarter Performance
Ascendis Pharma A/S unveiled loss for the second quarter of $ 2.17 per share, from the revenue of $ 1.58 million. The quarterly revenues escalated 464.29 percent compared with the same quarter last year. Wall street analysts are predicting, ASND to report 2Q20 loss of $ 1.71 per share from revenue of $ 2.53 million. The bottom line results missed street analysts by $ 0.46 or 26.9 percent, at the same time, top line results fell short of analysts by $ 0.95 million or 37.55 percent.
Stock Performance
Shares of Ascendis Pharma A/S traded low $ -6.79 or -4.03 percent on Tuesday, reaching $ 161.58 with volume of 169.20 thousand shares. Ascendis Pharma A/S has traded high as $ 169.53 and has cracked $ 161.23 on the downward trend
The closing price of $ 161.58, representing a 83.01 % increase from the 52 week low of $ 92.00 and a 5.55 % decrease over the 52 week high of $ 178.26.
The company has a market capital of $ 8.63 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 13th October 2020, maintained by Morgan Stanley at Overweight rating, with $ 194.00 target price.
Conference Call
Ascendis Pharma A/S will be hosting a conference call at 4:30 PM eastern time on 11th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.ascendispharma.com
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone has completed Phase I clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies.
